# Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

> **NCT03096847** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 502 (actual)

## Conditions studied

- Advanced Metastatic Breast Cancer

## Interventions

- **DRUG:** ribociclib
- **DRUG:** letrozole
- **DRUG:** goserelin

## Key facts

- **NCT ID:** NCT03096847
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-24
- **Primary completion:** 2018-12-11
- **Final completion:** 2020-02-06
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096847, "Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03096847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*